Browsing Tag
MIRACLE Trial
3 posts
Moleculin hits key inflection point as pivotal MIRACLE Phase 3 AML trial completes treatment for first 45 patients
Find out how Moleculin Biotech’s pivotal MIRACLE Phase 3 milestone for Annamycin could reshape treatment for relapsed AML as Q1 2026 data approaches.
Can Moleculin’s MIRACLE trial redefine AML treatment? Company to showcase study at leukemia event
Find out how Moleculin’s MIRACLE phase 3 trial could reshape AML treatment as the company presents its latest progress at the Madrid leukemia meeting.
Moleculin Biotech (NASDAQ: MBRX) launches stock offering to support pivotal cancer drug trial and IND filings
Moleculin Biotech to raise $5.9M to fund its Phase 3 trial for Annamycin and expand oncology pipeline. Explore what this means for AML treatment and investors.